Rhythm Pharmaceuticals (NASDAQ:RYTM) Releases Earnings Results, Beats Expectations By $0.08 EPS

Posted by Stanley Muller on Aug 4th, 2026

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.08, Zacks reports. Rhythm Pharmaceuticals had a negative net margin of 93.33% and a negative return on equity of 203.25%. The company’s revenue was up 46.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.75) earnings per share.

Here are the key takeaways from Rhythm Pharmaceuticals’ conference call:

IMCIVREE’s U.S. launch for acquired hypothalamic obesity showed strong early demand, with more than 400 start forms from approximately 300 prescribers in the first 14 weeks. Payers have been supportive, with policies covering about 25% of Medicaid lives and 35% of commercial lives by the end of Q2.
Global IMCIVREE net product sales rose 19% sequentially to $71.3 million, driven by the acquired HO launch, continued BBS growth, and international patient expansion. Management said reimbursed patients increased more than 20% quarter over quarter.
Weekly MC4R agonist RM-718 produced an average 11.6% BMI reduction at 16 weeks in seven acquired HO patients, comparable to setmelanotide and bivamelagon, with no generalized hyperpigmentation reported. However, the dataset remains small and included two early discontinuations related to injection-site reactions and nausea.
Rhythm expects acquired HO approval and launch in Japan by year-end 2026, followed by launches in Germany and other European markets during 2027. The company ended Q2 with approximately $331 million in cash and expects it to fund planned operations for at least 24 months, while continuing to evaluate the development path for Prader-Willi syndrome.

Rhythm Pharmaceuticals Stock Performance

Shares of RYTM stock traded up $0.81 during mid-day trading on Tuesday, reaching $103.58. The company’s stock had a trading volume of 364,084 shares, compared to its average volume of 784,331. The firm’s 50-day moving average is $100.87 and its two-hundred day moving average is $95.87. The company has a market cap of $7.10 billion, a P/E ratio of -33.00 and a beta of 1.92. Rhythm Pharmaceuticals has a 1-year low of $74.50 and a 1-year high of $122.20.

Analysts Set New Price Targets

Several research firms recently commented on RYTM. JPMorgan Chase & Co. initiated coverage on shares of Rhythm Pharmaceuticals in a research note on Monday, July 27th. They set an “overweight” rating and a $145.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a report on Friday, July 17th. Royal Bank Of Canada upped their price objective on shares of Rhythm Pharmaceuticals from $137.00 to $141.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Wall Street Zen upgraded shares of Rhythm Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Citigroup reissued a “market outperform” rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday, June 3rd. Fifteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $138.73.

View Our Latest Report on Rhythm Pharmaceuticals

Insider Buying and Selling at Rhythm Pharmaceuticals

In related news, Director Lynn A. Tetrault sold 37,000 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $100.32, for a total value of $3,711,840.00. Following the sale, the director owned 7,000 shares of the company’s stock, valued at $702,240. The trade was a 84.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in RYTM. Xponance LLC increased its stake in Rhythm Pharmaceuticals by 2.6% during the 4th quarter. Xponance LLC now owns 4,269 shares of the company’s stock worth $457,000 after purchasing an additional 107 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in Rhythm Pharmaceuticals by 39.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 399 shares of the company’s stock valued at $43,000 after buying an additional 113 shares in the last quarter. Captrust Financial Advisors boosted its holdings in shares of Rhythm Pharmaceuticals by 0.7% in the second quarter. Captrust Financial Advisors now owns 17,471 shares of the company’s stock valued at $1,104,000 after buying an additional 114 shares during the period. California State Teachers Retirement System boosted its holdings in shares of Rhythm Pharmaceuticals by 0.5% in the second quarter. California State Teachers Retirement System now owns 42,917 shares of the company’s stock valued at $2,712,000 after buying an additional 196 shares during the period. Finally, E Fund Management Co. Ltd. increased its position in shares of Rhythm Pharmaceuticals by 6.8% during the second quarter. E Fund Management Co. Ltd. now owns 5,761 shares of the company’s stock worth $364,000 after acquiring an additional 365 shares in the last quarter.

About Rhythm Pharmaceuticals

(Get Free Report)

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.